Artificial Intelligence
Wistar Institute Researchers Discover New Combination Therapy Approach for Metastatic Ovarian Cancer
Zhang Lab Demonstrates Novel Combination of Beta Glucan and Interferon Gamma Results in Tumor Regression Excerpt from the Press Release: PHILADELPHIA — (November 21, 2024) — The Wistar Institute’s Nan Zhang, Ph.D., assistant professor in the Ellen and Ronald Caplan Cancer Center’s Molecular and Cellular Oncogenesis Program, and lab have discovered a new approach to treating ovarian…
Read More
Studies to Be Presented at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting Excerpt from the Press Release: BOSTON, March 21, 2024 /PRNewswire/ — Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced excellent results across multiple clinical studies conducted with the University of Pittsburgh Medical Center (UPMC), Brigham…
Read More
Results show BPM31510 was well-tolerated, doubled progression free survival vs. chemotherapy alone BPGbio plans to further investigate BPM31510 as a first-line pancreatic cancer therapy with a phase 2b clinical trial Data validates BPM31510 mechanism of action and continues to show the success of BPGbio’s biology-first Bayesian AI-based approach to drug discovery Excerpt from the Press…
Read More
Excerpt from the Press Release: PHILADELPHIA and VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is thrilled to announce a new remarkable responder in our Phase 2 study of the…
Read More
Phase 1 trial enrolling patients with relapsed/refractory AML, MDS and B-cell ALL Excerpt from the Press Release: PALO ALTO, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported that the first patient has been…
Read More
Logica, an offering from Charles River and Valo Health, will be used to discover first-in-class therapeutics against high value targets in the Related Sciences portfolio Excerpt from the Press Release: WILMINGTON, Mass. & DENVER–(BUSINESS WIRE)–Charles River Laboratories International, Inc. (NYSE: CRL) and Related Sciences (“RS”), a data science-driven drug discovery firm, today announced a multi-program…
Read More
Excerpt from the Press Release: A paralysed man has regained the ability to walk smoothly using only his thoughts for the first time, researchers said on Wednesday, thanks to two implants that restored communication between brain and spinal cord. The patient Gert-Jan, who did not want to reveal his surname, said the breakthrough had given…
Read More
Integrated Biosciences’ new platform has potential to fuel advances in senolytic anti-aging compounds and longevity research AI-driven platform built on work pioneered at MIT identifies three candidates with comparable efficacy and superior medicinal chemistry relative to current investigational compounds Treatment of aged mice reduced number of senescent ‘zombie’ cells and lowered expression of senescence-associated genes…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., Feb. 2, 2023 /PRNewswire/ — Via Scientific, Inc., a new Cambridge based technology and AI company, is proud to announce the launch of Foundry, a multi-omics accelerator platform focused on significantly shortening the path to scientific breakthroughs. The Foundry platform was originally developed at UMass Chan Medical School;…
Read More
Partnership brings Iterative Scopes’ AI Recruitment technology to One GI® Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Iterative Scopes, a pioneer in precision-medicine technologies for gastroenterology, announced today that it has partnered with One GI®, a gastroenterology management services organization (MSO), to bring its AI Recruitment (AIR) technology to One GI’s clinical research. Initially, One…
Read More